14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BDRX vs SRTM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over SRTM (SRTM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDRX carries a Unified Composite Score of 36.0/100 (SELL) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas SRTM carries 47.6/100 (HOLD) at $0.08 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While SRTM currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. BDRX 36.0/100 SELL), BDRX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-64.1% vs. N/A YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BDRX vs SRTM. Trailing 12-month operating profitability (BDRX 0.0% vs SRTM N/A) and valuation multiples (BDRX N/M vs SRTM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BDRX vs SRTM Key Questions & Quantitative Answers
As of Nov 20, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over SRTM (SRTM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDRX carries a Unified Composite Score of 36.0/100 (SELL) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas SRTM carries 47.6/100 (HOLD) at $0.08 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While SRTM currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. BDRX 36.0/100 SELL), BDRX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-64.1% vs. N/A YoY).
BDRX leads the Growth & Scale pillar: BDRX posts -64.1% YoY revenue growth and +0.0% YoY earnings growth on $83,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRTM at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BDRX generates $83,000 in USD-normalized revenue versus N/A for SRTM. In operating R&D and SG&A reinvestment, BDRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRTM.
BDRX screens cheaper on headline valuation multiples. BDRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.6x EV/Revenue (unreported EBITDA margin), whereas SRTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BDRX (-42.0% ROE) versus SRTM (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, BDRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.62β · 2621% Vol realized risk). By comparison, SRTM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.